Year All20242023202220212020201920182017201620152014 Apr 29, 2024 Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS) Apr 19, 2024 Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Mar 08, 2024 Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Mar 06, 2024 Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results Feb 22, 2024 Soleno Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference Feb 01, 2024 Soleno Therapeutics to Present at Upcoming February Investor Conferences Jan 29, 2024 Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jan 24, 2024 Soleno Therapeutics Strengthens Leadership Team with Key Appointments Jan 05, 2024 Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Nov 10, 2023 Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 29, 2024 Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)
Mar 06, 2024 Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results